NUSINERSEN

Information current as at: 1 September 2024

PBAC meeting date: July 2019
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Spinraza®
Pharmaceutical company:
Biogen Australia Pty Ltd
Condition/indication:
(therapeutic use)
  • Spinal muscular atrophy
PBAC Submission type:
Change to listing (Major)
Comment:
--
Related medicines:

Progress Details

Submission received for:
July 2019 PBAC meeting
Opportunity for consumer comment:
Open 01/05/2019 and close 12/06/2019 (see PBS Website)
PBAC meeting:
Held on 10/07/2019
PBAC outcome published:
Deferred (see PBAC Outcomes)
Lodgement of required documentation:
Not applicable
Agreement to listing arrangements:
Not applicable
Government processes:
Not applicable
Medicine listed on the PBS:
Not applicable

Case ID: a032

Page last updated: 02 May 2024

v.9.18